Research progress on radiotherapy and radiation-associated adverse effects of high-risk neuroblastoma
10.3760/cma.j.cn113030-20211111-00457
- VernacularTitle:高危神经母细胞瘤放疗及相关不良反应研究进展
- Author:
Shidi ZHANG
1
;
Yongrui BAI
;
Haiyan CHEN
Author Information
1. 上海交通大学医学院附属仁济医院放疗科，上海 200127
- Keywords:
Neuroblastoma;
Radiotherapy;
Primary lesions;
Metastatic sites;
Adverse effects
- From:
Chinese Journal of Radiation Oncology
2023;32(2):174-178
- CountryChina
- Language:Chinese
-
Abstract:
High-risk neuroblastoma (NB) is highly aggressive and has poor prognosis. Treatment of NB mainly includes comprehensive therapies, of which radiotherapy serves as a part of consolidation therapy. For patients who receive complete resection of the primary lesion, usually an irradiation dose of 21-23.4 Gy is given; for patients with incomplete resection, further study focused on radiation dose is necessary. Recurrence is most commonly observed in the bone lesions involved at presentation. Currently, the principle of irradiation to the metastatic sites is to treat lesions where metaio-dobenzylguanidine (MIBG) uptake remains positive after induction chemotherapy, or those become negative uptake but still at high risk of recurrence. On the premise of lacking of MIBG imaging, positron emission tomography CT (PET-CT) may assist in screening for metastatic sites requiring irradiation. The late side effects of radiotherapy are mainly mild musculoskeletal abnormalities. No significant increase is observed in the incidence of second primary tumor during short-term follow-up.
